Share this page!

Enter URL or ID to Unroll

You can paste full URL like: https://x.com/threadreaderapp/status/1644127596119195649
or just the ID like: 1644127596119195649

How to get URL link on X (Twitter) App

  1. On the Twitter thread, click on or icon on the bottom
  2. Click again on or Share Via icon
  3. Click on Copy Link to Tweet
  4. Paste it above and click "Unroll Thread"!
  5. More info at Twitter Help
David Hyman Profile picture
David Hyman
@DHymanMD
Chief Medical Officer, Loxo Oncology and Lilly Oncology at @LillyPad. Former Chief of Early Drug Development at MSK. Personal account, opinions my own.
Apr 1, 2019 • 8 tweets • 6 min read
Missed the talk? Here's a summary of latest data on the selective next-gen TRK inhibitor LOXO-195 (BAY 2731954). On-target resistance to current inhibitors driven by kinase mutations in 3 positions (SF, xDFG, GK) - SF likely most common. #AACR19 @sloan_kettering @AACR 1/x LOXO-195 evaluated in 2 programs: formal Phase 1 dose escalation and @FDAOncology #ExpandedAccess program 👏 (for pts unable to enroll in P1). Here's the key eligibility and combined patient demographics. 15 tumor types. 30 pts TRKi resistant, 1 intolerant. 2/x
Mar 13, 2019 • 8 tweets • 7 min read
New at @nature - Efficacy of MEK inhibition in patients with histiocytosis. The culmination of an amazing 7-year collaboration @sloan_kettering with Eli Diamond @AbdelWahablab @ECDGA @Histiocytosis @Roche and many others! rdcu.be/bqSIq [1/x] We stumbled into histiocytosis after Barret Rollins' lab discovered BRAF V600 mutations in ~50% of LCH, followed later by Julian Haroche making similar observations in ECD.
bloodjournal.org/content/116/11…
bloodjournal.org/content/120/13… [2/x]
Feb 28, 2019 • 5 tweets • 4 min read
Easing 'compassionate use' access to investigational drugs has been a major priority for the @FDAOncology @SGottliebFDA @tmprowell @BlumenthalG - now in @JAMAOnc our analysis of outcomes from this mechanism over 5 years @sloan_kettering ja.ma/2Ej78li [1/5] Key findings: 208 applications IRB-approved (185 administered), 43 cancer types treated, 66 unique products. ORR 20.1% (95% CI, 14.2%-27.2%). PFS at 1-year 24.5% (95% CI, 18.2%-31.4%). Meaningful benefit - albeit in minority of patients. [2/5]
Apr 17, 2018 • 15 tweets • 13 min read
Great #PrecisionDecision debate at #AACR18 with @VinayPrasadMD and @baslega1! Missed it? Who is ready for my first (and maybe only) TWEETORIAL? @AACR @sloan_kettering 1/15 But before I start, I have to admit that I was a bit intimidated to take on @VinayPrasadMD – the Twitter stats comparison wasn’t flattering. But I do have him beat on middle initials. #PrecisionDecision 2/15